Compare Snowflake Inc (SNOW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs TG Therapeutics Inc — how do they compare? Snowflake Inc trades at $332.2 (market cap $116.01B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Snowflake Inc is far larger — about 15.2× TG Therapeutics Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SNOW | TGTX | |
|---|---|---|
Market Cap | $116.01B | $7.64B |
Sector | Technology | Health |
52-Week High | $334.70 | $59.06 |
52-Week Low | $121.11 | $26.94 |
Enterprise Value | $115.82B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $334.30, down 0.12% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $3.63 billion in 2025, though net losses persist at -$1.29 billion. Recent news highlights AI platform enhancements and investor conferences, with earnings beats in the last three quarters.
Outlook remains growth-focused with AI adoption driving upside, but premium valuation (P/S 22.66) and sustained losses pose risks. Analyst consensus is bullish with an 80.77% buy rating, though competition and margin pressure require monitoring for stock investors.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
